Skip to main content
. 2012 Jan 17;7(1):e29894. doi: 10.1371/journal.pone.0029894

Figure 5. Effects of JES6-1 treatment on splenic CD4+ T cell phenotype and proliferative response to PRBC during chronic P. chabaudi malaria.

Figure 5

(A) C57BL/6 mice were treated with JES6-1 mAb on days 0, 2 and 4 p.i. with 106 PRBC. On day 20 p.i., CD62L and CD45RB expression was evaluated in gated CD4+ T cells. Numbers inside dot plots refer to means ± SD (n = 3–4) of cell percentages in each gate. (B) CD69 expression was analyzed in gated CD4+ T cells from the same groups of mice. (C) In vitro proliferative response of PRBC-stimulated CD4+ cells cultured in the presence or absence of JES6-1 mAb. CD4+ T cells were obtained from 30-day infected mice treated in vivo or not with JES6-1 mAb on days 0, 2 and 4 of infection. Histograms show CFSE fluorescence in gated CD4+ T cells. The means ± SD (n = 3–4) of the percentages of replicating (CFSELO) cells are shown. In A–C, significant differences compared experimental conditions *p<0.05 with cells from non-infected (NI) mice; **p<0.05 with non-treated (NT) mice or cells; and # p<0.05 with non-treated (NT) cells from JES6-1-treated mice. Data are representative of two separate experiments.